timothy sykes logo
TNXP Stock Surges: Analyzing Recent Performance Thumbnail
G Google News

TNXP Stock Surges: Analyzing Recent Performance

TIM SYKES•UPDATED AUG. 12, 2025, 5:04 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Tonix Pharmaceuticals’ stocks have been trading up by 31.64 percent following promising FDA certification news.

  • The “Move Fibro Forward” campaign initiated by Tonix Pharmaceuticals aims to raise awareness and provide support for individuals affected by fibromyalgia.

  • Awaiting the FDA’s decision, Tonix anticipates the approval of TNX-102 SL for fibromyalgia treatment, following significant achievements in Q2 2025, such as successful Phase 3 studies.

  • Tonix Pharmaceuticals highlights advancements in cancer research through collaboration with Columbia University.

  • Tonix Pharmaceuticals has been added to the Russell Indexes, bolstering its profile and market visibility.

Candlestick Chart

Live Update At 17:03:24 EST: On Tuesday, August 12, 2025 Tonix Pharmaceuticals Holding Corp. stock [NASDAQ: TNXP] is trending up by 31.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview and Stock Performance

Trading can be a daunting task, especially in volatile markets. Many traders often grapple with the emotional rollercoaster of potentially losing money. However, it’s crucial to maintain perspective and discipline. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” This mindset can help traders avoid significant losses by emphasizing the importance of preserving capital rather than risking it for uncertain gains. Adopting such a pragmatic approach can ultimately lead to more sustainable and sound trading practices, ensuring that traders remain in the game for the long haul.

Recently, Tonix Pharmaceuticals has displayed financial resilience despite some hurdles. With a huge cash reserve, they reported $125.3M on Jun 30, 2025, that is expected to cover operations until Q3 2026, providing a safety net amidst market volatility. However, the financial statements reveal both challenges and opportunities. Despite a quarter-over-quarter drop in Q2 revenue, the firm is anticipating FDA approval for its fibromyalgia treatment, TNX-102 SL. This anticipation has sparked interest and optimism in the market, as investors foresee a significant uplift if the approval comes through.

Examining TNXP’s stock data, the share price recently closed at $59.76. The movements have been marked by bursts of activity, influenced by news surrounding the company’s potential FDA drug approval and its addition to the Russell Indexes. Over the past few trading days, TNXP’s stock swung dramatically, demonstrating the market’s reaction to positive news and upcoming possibilities for the company.

Upon reflection, the technical chart showcases a swift rise and fall pattern, a testament to the volatility inherent in this sector. Interestingly, the intraday activity on Aug 12, 2025, observed peaks and troughs, each echoing the narrative surrounding upcoming FDA approvals and strategic collaborations in research.

On the metrics front, whilst the profitability ratios paint a challenging profitability landscape, the company’s ebit margin reflects the potential for improvement. The company’s high current ratio demonstrates substantial liquidity, a compelling cushion against unforeseen exigencies.

News Analysis: Catalysts for TNXP’s Price Movement

Cash Reserves Expectation

With Tonix Pharmaceuticals banking on its cash reserves to support operations until Q3 of 2026, investors are assured of the company’s financial steams in the short term. This news acts as a soft cushion, assuaging potential shareholder concerns about short-term financial duress.

Campaign “Move Fibro Forward”

By launching the “Move Fibro Forward” campaign, Tonix has effectively positioned itself as not merely a pharmaceutical entity, but as an advocate for the fibromyalgia community. This social responsibility aspect can potentially resonate with conscientious investors, driving interest and potentially increasing stock demand.

More Breaking News

Awaiting FDA Approval

Investors eagerly await the FDA’s ruling on TNX-102 SL’s approval, as successful feedback could kick-start a rally in the stock price, making it a lucrative proposition in the immediate future. Meanwhile, the steady flow of favorable news assists in maintaining the buoyant sentiment around TNXP.

Research Collaboration

The partnership with Columbia University represents a venture into potentially rewarding cancer research. Such collaborative innovation projects are highly appealing to the market, since they broaden Tonix’s portfolio and may offer substantial long-term rewards.

Inclusion in Russell Indexes

Being added to the Russell Indexes is a pivotal milestone. This development signals market recognition, potentially drawing in a new wave of institutional investors eager to tap into promising sectors like biotechnology.

The Big Picture: What’s Next for TNXP?

Tonix Pharmaceuticals finds itself at a juncture laden with promise and stirring queries. As the company navigates through the shifting sands of the market with its mixture of immediate revenue challenges and tantalizing growth opportunities, stakeholders will keenly observe its strategic maneuvers. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”

To summarize, the news pieces combined create a compelling narrative. They offer glimmers of optimism amidst financial challenges. With advancing variability and trader speculations, TNXP is uniquely positioned to surge forward propelled by imminent FDA decisions and strategic alliances. Yet, as is customary with penny stocks, like balloons carried by unpredictable winds, the journey is not without its set of challenges.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading TNXP

Millionaire's
POV on TNXP

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”